Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β(2)-agonists in obstructive lung diseases: a population-based, observational st...

por Björnsdóttir, U S, Sigurðardóttir, S T, Jonsson, J S, Jonsson, M, Telg, G, Thuresson, M, Naya, I, Gizurarson, S
Publicado 2014

IDF2022-0622 Mortality and cardiorenal disease in type 1 and type 2 diabetes after COVID-19 and influenza hospitalization in Sweden

por Kristófl, R., Bodegard, J., Ritsinger, V., Thuresson, M., Nathanson, D., Nyström, T., Norhammar, A., Eriksson, J.W.
Publicado 2023

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients

por Hasvold, L P, Bodegård, J, Thuresson, M, Stålhammar, J, Hammar, N, Sundström, J, Russell, D, Kjeldsen, S E
Publicado 2014

P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE P...

por Schjesvold, F, Ludwig, H, Delimpasi, S, Robak, P, Mateos, M, Sandberg, A, Thuresson, M, Norin, S, Richardson, P, Sonneveld, P
Publicado 2023

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG...

por Mateos, M, Szarejko, M, Bila, J, Schjesvold, F, Spicka, I, Maisnar, V, Jurczyszyn, A, Grudeva-Popova, Z, Hajek, R, Usenko, G, Thuresson, M, Norin, S, Jarefors, S, Richardson, P, Pour, L
Publicado 2023